What is HC Wainwright’s Estimate for GALT FY2026 Earnings?

Galectin Therapeutics Inc. (NASDAQ:GALT) – Equities research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of Galectin Therapeutics in a research report issued on Tuesday, March 31st. HC Wainwright analyst M. Keller now forecasts that the company will post earnings per share of ($0.31) for the year, up from their prior estimate of ($0.41). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ FY2027 earnings at ($0.33) EPS.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Galectin Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $11.00.

Galectin Therapeutics Stock Down 0.4%

Shares of GALT stock opened at $2.67 on Friday. Galectin Therapeutics has a 12 month low of $1.12 and a 12 month high of $7.13. The company’s fifty day simple moving average is $2.95 and its 200-day simple moving average is $4.19. The firm has a market cap of $175.77 million, a PE ratio of -5.56 and a beta of 1.03.

Institutional Investors Weigh In On Galectin Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada grew its holdings in Galectin Therapeutics by 1,197.3% during the fourth quarter. Royal Bank of Canada now owns 6,175 shares of the company’s stock worth $25,000 after purchasing an additional 5,699 shares during the period. Atwood & Palmer Inc. bought a new stake in Galectin Therapeutics in the third quarter valued at approximately $42,000. Invesco Ltd. bought a new stake in Galectin Therapeutics in the fourth quarter valued at approximately $43,000. Archer Investment Corp acquired a new stake in shares of Galectin Therapeutics in the third quarter valued at approximately $47,000. Finally, Cetera Investment Advisers bought a new position in shares of Galectin Therapeutics during the 4th quarter worth approximately $59,000. 11.68% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Khurram Jamil sold 25,499 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $3.90, for a total value of $99,446.10. Following the completion of the transaction, the insider directly owned 21,446 shares of the company’s stock, valued at approximately $83,639.40. This trade represents a 54.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joel Lewis sold 37,698 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $3.58, for a total transaction of $134,958.84. Following the transaction, the chief executive officer owned 832,592 shares in the company, valued at approximately $2,980,679.36. The trade was a 4.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 158,460 shares of company stock valued at $596,165 in the last 90 days. 52.60% of the stock is currently owned by insiders.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.